Article Text
Statistics from Altmetric.com
It is not a bad idea to assess whether direct-to-consumer (DTC) genomic tests are a threat to or instead an enhancement of autonomy, as is done in the article ‘Direct to consumer genomics on the scales of autonomy’ by Effy Vayena.1 Autonomy has played a starring role in ethical discussions surrounding DTC genomic testing, but has taken many different shapes. Vayena deploys Joseph Raz’ conception of autonomy, which entails that genomic tests enhance autonomy if they present the consumer with an adequate—that is, varied and morally worthwhile—range of options to choose from, which should promote the consumer's interests. She states that genomic tests generate ‘plural utilities’ that are taken to expand the range of valuable options and therewith to satisfy Raz’ thick conception of autonomy. Thus, Vayena makes an autonomy-based case in favour of legal permissibility of commercially offered genomic tests. The analysis however overlooks three crucial considerations.
First, there is no such thing as ‘genomic testing’. Plenitudes of genomic tests have been put to market, with different underlying techniques and test characteristics, different diseases and other phenotypical traits included in the testing offer, and …
Footnotes
-
Competing interests None.
-
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Genetics
- Genetics
- Genetics
- The concise argument
Read the full text or download the PDF:
Other content recommended for you
- Direct-to-consumer genomics on the scales of autonomy
- Personal utility is inherent to direct-to-consumer genomic testing
- Personal utility in genomic testing: is there such a thing?
- Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation
- Impact of direct-to-consumer genomic testing at long term follow-up
- A practical guide to interpretation and clinical application of personal genomic screening
- ‘There is a lot of good in knowing, but there is also a lot of downs’: public views on ethical considerations in population genomic screening
- Privacy, autonomy and direct-to-consumer genetic testing: a response to Vayena
- Adopted individuals’ interest in elective genomic testing
- Genomic intensive care: should we perform genome testing in critically ill newborns?